adebrelimab + RGL-270

Adebrelimab + RGL-270 is an investigational combination therapy consisting of two components: - **Adebrelimab** is a humanized monoclonal antibody targeting programmed death-ligand 1 (PD-L1), functioning as an immune checkpoint inhibitor to enhance anti-tumor immune responses. - **RGL-270** is a personalized neoantigen mRNA tumor vaccine designed to stimulate the patient's immune system against tumor-specific antigens. The combination aims to synergistically boost anti-tumor immunity by blocking PD-L1-mediated immunosuppression and actively priming T cells against patient-specific cancer neoantigens. This regimen is being studied primarily in solid tumors, including non-small cell lung cancer and pancreatic adenocarcinoma[1][2][3].

Other names

HRXG-K-1939 (for the mRNA vaccine component)